Comparative in Vitro Study of the Immunomodulatory Activity of Humanized and Chimeric Anti-CD25 Monoclonal Antibodies

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2003 Nov 25

PMID 14632747

Citations 6

Authors

B Kircher

K Latzer

G Gastl

D Nachbaur

Affiliations

Soon will be listed here.

Abstract

Humanized or chimeric monoclonal antibodies (MoAbs) directed against the interleukin-2 (IL-2) receptor alpha-chain, CD25, are promising immunosuppressive agents due to improved pharmacokinetic profiles and less toxicity. These MoAbs have been used effectively in preventing and/or treating rejection in solid organ transplantation and are currently under investigation for prevention/treatment of graft-versus-host disease (GvHD) in stem cell transplantation. We analysed the in vitro activities of the chimeric anti-CD25 MoAb basiliximab and the humanized anti-CD25 MoAb daclizumab in various test systems for alloimmune response and T cell activation in comparison to cyclosporin A (CsA) and prednisolone. Anti-CD3- and alloantigen-induced T cell proliferation were decreased significantly by the anti-CD25 MoAbs in a dose-dependent fashion. At a concentration of 10 ng/ml daclizumab and CsA synergistically decreased T cell proliferation of mixed lymphocyte cultures, whereas basiliximab showed only subadditive activity. Simultaneous addition of the anti-CD25 MoAbs and prednisolone did not result in combined activity. Addition of exogenous IL-2 completely overcame the inhibitory effect on T cell proliferation of both anti-CD25 MoAbs, but not that of CsA and prednisolone. Anti-CD25 MoAbs inhibited the generation of antigen-specific cytotoxic T lymphocytes in a limiting dilution assay, whereas they showed no effect on the cytolytic activity of established antigen-specific T cell clones. This in vitro study demonstrates strong immunosuppressive activity by both chimeric and humanized MoAbs against CD25. The combined activity with CsA justifies their early use for prevention rather than treatment of GvHD.

Citing Articles

Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft--Host Disease.

Shen M, Li J, Zhang X, Xu L, Wang Y, Liu K Front Immunol. 2021; 12:749266.

PMID: 34621279 PMC: 8490710. DOI: 10.3389/fimmu.2021.749266.

A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling.

Goldberg R, Clough J, Roberts L, Sanchez J, Kordasti S, Petrov N J Crohns Colitis. 2021; 15(12):2054-2065.

PMID: 34120187 PMC: 8684452. DOI: 10.1093/ecco-jcc/jjab103.

Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.

Nguyen A, Gresle M, Marshall T, Butzkueven H, Field J Br J Pharmacol. 2017; 174(13):1895-1907.

PMID: 28319650 PMC: 5466523. DOI: 10.1111/bph.13780.

Haploidentical hematopoietic stem cell transplantation following myeloablative conditioning regimens in hematologic diseases with G-CSF-mobilized peripheral blood stem cells grafts without T cell depletion: a single center report of 38 cases.

Lu R, Miao K, Zhang R, Hong M, Xu J, Zhu Y Med Oncol. 2014; 31(8):81.

PMID: 25001087 DOI: 10.1007/s12032-014-0081-x.

HDAC inhibition in lupus models.

Reilly C, Regna N, Mishra N Mol Med. 2011; 17(5-6):417-25.

PMID: 21327298 PMC: 3105141. DOI: 10.2119/molmed.2011.00055.

References

Ferrara J, Levy R, Chao N . Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999; 5(6):347-56. DOI: 10.1016/s1083-8791(99)70011-x. View

Przepiorka D, Kernan N, Ippoliti C, Papadopoulos E, Giralt S, Khouri I . Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 1999; 95(1):83-9. View

Ferrara J, Holler E, Blazar B . Monoclonal antibody and receptor antagonist therapy for GVHD. Cancer Treat Res. 2000; 101:331-68. DOI: 10.1007/978-1-4615-4987-1_15. View

Champlin R, Passweg J, Zhang M, Rowlings P, Pelz C, Atkinson K . T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000; 95(12):3996-4003. View

Willenbacher W, Basara N, Blau I, Fauser A, Kiehl M . Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol. 2001; 112(3):820-3. DOI: 10.1046/j.1365-2141.2001.02582.x. View

Vincenti F . Interleukin-2 receptor monoclonal antibodies in renal transplantation: current use and emerging regimens. Transplant Proc. 2001; 33(7-8):3169-71. DOI: 10.1016/s0041-1345(01)02349-1. View

Calmus Y, Scheele J, Gonzalez-Pinto I, Jaurrieta E, Klar E, Pageaux G . Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 2002; 8(2):123-31. DOI: 10.1053/jlts.2002.30882. View

Kircher B, Stevanovic S, Urbanek M, Mitterschiffthaler A, Rammensee H, Grunewald K . Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br J Haematol. 2002; 117(4):935-9. DOI: 10.1046/j.1365-2141.2002.03536.x. View

Niemeyer G, Koch M, Light S, Kuse E, Nashan B . Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant. 2002; 2(5):454-60. DOI: 10.1034/j.1600-6143.2002.20510.x. View

10.

Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G . Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet. 2002; 360(9327):130-7. DOI: 10.1016/S0140-6736(02)09413-8. View

11.

Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R . Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002; 30(12):899-903. DOI: 10.1038/sj.bmt.1703737. View

12.

Zier K, Huber C, BRAUNSTEINER H . Linear density gradient separation of human lymphocyte subsets. I. Analysis by mixed leukocyte culture and cell-mediated lympholysis responses. Eur J Immunol. 1977; 7(6):366-70. DOI: 10.1002/eji.1830070608. View

13.

Huber C, Fink U, Leibold W, Schmalzl F, Peterson P, Klareskog L . The role of adherent HLA-DR+ mononuclear cells in autologous and allogeneic MLR. J Immunol. 1981; 127(2):726-31. View

14.

Depper J, Leonard W, Robb R, Waldmann T, Greene W . Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol. 1983; 131(2):690-6. View

15.

Storb R, Deeg H, Whitehead J, Appelbaum F, Beatty P, Bensinger W . Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986; 314(12):729-35. DOI: 10.1056/NEJM198603203141201. View

16.

Kupiec-Weglinski J, DIAMANTSTEIN T, Tilney N, Strom T . Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci U S A. 1986; 83(8):2624-7. PMC: 323351. DOI: 10.1073/pnas.83.8.2624. View

17.

Tellides G, Dallman M, Morris P . Synergistic interaction of cyclosporine A with interleukin 2 receptor monoclonal antibody therapy. Transplant Proc. 1988; 20(2 Suppl 2):202-6. View

18.

Kupiec-Weglinski J, Hahn H, Kirkman R, Volk H, Mouzaki A, DISTEFANO R . Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. Transplant Proc. 1988; 20(2 Suppl 2):207-16. View

19.

Storb R, Deeg H, Pepe M, Appelbaum F, Anasetti C, Beatty P . Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989; 73(6):1729-34. View

20.

Kaminski E, Hows J, Man S, Brookes P, Mackinnon S, Hughes T . Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation. 1989; 48(4):608-13. View